SCHEMBL21343079

SCHEMBL21343079

CC1CC(=O)N(CCCCCC(=O)NNN)C1=O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ CYP19A1 P11511 4/20 0.39
▸ HDAC8 Q9BY41 9/20 0.37
▸ HDAC3 O15379 8/20 0.37
▸ HDAC4 P56524 8/20 0.37
▸ HDAC1 Q13547 8/20 0.37
▸ HDAC7 Q8WUI4 8/20 0.37
▸ HDAC2 Q92769 8/20 0.37
▸ HDAC10 Q969S8 8/20 0.37
▸ HDAC11 Q96DB2 8/20 0.37
▸ HDAC6 Q9UBN7 8/20 0.37
▸ HDAC9 Q9UKV0 8/20 0.37
▸ HDAC5 Q9UQL6 8/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ MAPK1 P28482 1/20 0.35
▸ TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21342730 0.89 HPGD (0.41) HPGDSMN1; SMN2HTTCYP19A1HDAC8
SCHEMBL21342728 0.89 HPGD (0.41) HPGDSMN1; SMN2HTTCYP19A1HDAC8
SCHEMBL22989393 0.87 HDAC1 (0.42) HPGDSMN1; SMN2HTTHDAC8HDAC3
SCHEMBL15981168 0.87 SMN1; SMN2 (0.40) HPGDSMN1; SMN2HTTCYP19A1HDAC8
SCHEMBL15691941 0.87 CYP19A1 (0.41) HPGDSMN1; SMN2HTTCYP19A1HDAC8
SCHEMBL13950301 0.85 HPGD (0.42) HPGDSMN1; SMN2HTTHDAC8HDAC3
SCHEMBL22644055 0.83 CYP19A1 (0.41) HPGDSMN1; SMN2HTTCYP19A1ALDH1A1
SCHEMBL17453141 0.83 HPGD (0.40) HPGDSMN1; SMN2HTTHDAC8HDAC3
SCHEMBL17453142 0.82 HPGD (0.40) HPGDSMN1; SMN2HTTHDAC8HDAC3
SCHEMBL10283656 0.81 HPGD (0.50) HPGDSMN1; SMN2HTTHDAC8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023201337-A2 METHOD OF TREATING UVEITIS WITH MULTIVALENT PROTEIN-HYALURONIC ACID POLYMER CONJUGATE VALITOR, INC. (US) 2023-10-19 — — WO disclosed
WO-2023201336-A2 HUMANIZED MULTIVALENT PROTEIN CONJUGATES VALITOR, INC. (US) 2023-10-19 — — WO disclosed
WO-2023201335-A2 PURIFIED MULTIVALENT PROTEIN-HYALURONIC ACID POLYMER CONJUGATES VALITOR, INC. (US) 2023-10-19 — — WO disclosed
WO-2023183786-A2 METHOD OF TREATING A CANCER WITH A MULTIVALENT PEPTIDE CONJUGATE VALITOR, INC. (US) 2023-09-28 — — WO disclosed
WO-2019173777-A1 MULTIVALENT PEPTIDE CONJUGATES FOR SUSTAINED INTRA-ARTICULAR TREATMENT OF JOINT INFLAMMATION VALITOR, INC. (US) 2019-09-12 — — WO disclosed
Send feedback